Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a report released on Friday.

Other analysts also recently issued reports about the company. Piper Sandler upped their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Finally, Robert W. Baird dropped their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Down 0.6 %

KPTI stock opened at $0.84 on Friday. The company’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $0.89. Karyopharm Therapeutics has a 12 month low of $0.62 and a 12 month high of $1.95. The firm has a market cap of $105.27 million, a P/E ratio of -0.74 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same period last year, the business earned ($0.30) earnings per share. Equities analysts predict that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth $143,000. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics in the second quarter worth $167,000. Exchange Traded Concepts LLC grew its stake in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares during the last quarter. Finally, FMR LLC increased its holdings in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares during the period. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).